USD 10.68
↑ 0.28 (2.69%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| BNTC | 2.7 | 1.5 | 8.9 | 24.2 | 20.7 | 176.7 | -81.7 | -93.4 | -99.6 | -99.8 |
| S&P 500 | -1.3 | -1.8 | 1.0 | 5.9 | 10.6 | 30.4 | 25.4 | 88.1 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | BNTC |
| name | Benitec Biopharma Inc. |
| price | 10.68 |
| changes percentage | 2.69 |
| change | 0.28 |
| day low | 10.31 |
| day high | 10.78 |
| year high | 12.89 |
| year low | 2.69 |
| market cap | 211624200 |
| price avg 50 | 9.87 |
| price avg 200 | 7.76 |
| exchange | NASDAQ |
| volume | 45339 |
| avg volume | 30175 |
| open | 10.31 |
| previous close | 10.40 |
| eps | -5.51 |
| pe | -1.94 |
| earnings announcement | 2024-11-14T12:00:00.000+0000 |
| shares outstanding | 19815000 |
| timestamp | 2024-11-15 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001808898 | |||
| revenue | 216000 | 75000 | 188.00 |
| gross profit | 108000 | -306000 | 135.29 |
| gross profit ratio | 0.5 | -4.08 | 112.25 |
| research and development expenses | 15609000 | 12774000 | 22.19 |
| operating expenses | 22382000 | 19156000 | 16.84 |
| interest income | 0 | 49546 | -100.00 |
| interest expense | 904000 | 33000 | 2,639.39 |
| ebitda | -22490000 | -18700000 | -20.27 |
| ebitdaratio | -104.12 | -249.73 | 58.31 |
| operating income | -22490000 | -19081000 | -17.87 |
| operating income ratio | -104.12 | -254.41 | 59.07 |
| net income | -21751000 | -19562000 | -11.19 |
| net income ratio | -100.7 | -260.83 | 61.39 |
| eps | -5.36 | -14.12 | 62.04 |
Revenue Growth: revenue decreased to 0 million in 2024 from 0 million in 2023 representing a change of 188.0%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 22 million in 2024 from 19 million in 2023 representing a change of 16.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Gross Profit: Gross Profit increased to 0 million in 2024 from 0 million in 2023 representing a change of 135.29%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 16 million in 2024 from 13 million in 2023 representing a change of 22.19%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -22 million in 2024 from -19 million in 2023 representing a change of -20.27%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -22 million in 2024 from -19 million in 2023 representing a change of -17.87%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -22 million in 2024 from -20 million in 2023 representing a change of -11.19%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -5.36 in 2024 from -5.36 in 2023 representing a change of 62.04%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001808898 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -91000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 3585000 | 3512000 | 2.08 |
| operating expenses | 5791000 | 5548000 | 4.38 |
| interest income | 0 | 0 | NaN |
| interest expense | 604000 | 0 | NaN |
| ebitda | -5791000 | -5522000 | -4.87 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -5791000 | -5548000 | -4.38 |
| operating income ratio | 0 | 0 | NaN |
| net income | -5059000 | -4720000 | -7.18 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.48 | -1.31 | 63.36 |
Gross Profit: Gross Profit increased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 4 million in 2025Q1 from 4 million in 2024Q4 representing a change of 2.08%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -6 million in 2025Q1 from -6 million in 2024Q4 representing a change of -4.87%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -6 million in 2025Q1 from -6 million in 2024Q4 representing a change of -4.38%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -5 million in 2025Q1 from -5 million in 2024Q4 representing a change of -7.18%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.48 in 2025Q1 from -0.48 in 2024Q4 representing a change of 63.36%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 6 million in 2025Q1 from 6 million in 2024Q4 representing a change of 4.38%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001808898 | |||
| total assets | 52210000 | 4464000 | 1,069.58 |
| total liabilities | 4962000 | 4262000 | 16.42 |
| total equity | 47248000 | 202000 | 23,290.10 |
| cash and cash equivalents | 50866000 | 2477000 | 1,953.53 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 51674000 | 3729000 | 1,285.73 |
| total non current assets | 536000 | 735000 | -27.07 |
| total current liabilities | 4924000 | 3978000 | 23.78 |
| total non current liabilities | 38000 | 284000 | -86.62 |
| common stock | 1000 | 0 | NaN |
| retained earnings | -190259000 | -167889000 | -13.32 |
| total debt | 284000 | 559000 | -49.19 |
Total Assets: Total Assets increased to 52 million in 2024 from 4 million in 2023 representing a change of 1069.58%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 47 million in 2024 from 0 million in 2023 representing a change of 23290.1%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 51 million in 2024 from 2 million in 2023 representing a change of 1953.53%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 52 million in 2024 from 4 million in 2023 representing a change of 1285.73%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024 from 0 in 2023 representing a change of nan%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 0 million in 2024 from 1 million in 2023 representing a change of -49.19%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 5 million in 2024 from 4 million in 2023 representing a change of 16.42%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 5 million in 2024 from 4 million in 2023 representing a change of 23.78%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -190 million in 2024 from -168 million in 2023 representing a change of -13.32%. This indicates an accumulated losses.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001808898 | |||
| total assets | 68774000 | 52210000 | 31.73 |
| total liabilities | 4594000 | 4962000 | -7.42 |
| total equity | 64180000 | 47248000 | 35.84 |
| cash and cash equivalents | 67841000 | 50866000 | 33.37 |
| short term investments | 0 | 63000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 68335000 | 51674000 | 32.24 |
| total non current assets | 439000 | 536000 | -18.10 |
| total current liabilities | 4553000 | 4924000 | -7.53 |
| total non current liabilities | 41000 | 38000 | 7.89 |
| common stock | 1000 | 1000 | 0.00 |
| retained earnings | -195318000 | -190259000 | -2.66 |
| total debt | 211000 | 284000 | -25.70 |
Total Assets: Total Assets increased to 69 million in 2025Q1 from 52 million in 2024Q4 representing a change of 31.73%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 5 million in 2025Q1 from 5 million in 2024Q4 representing a change of -7.42%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 64 million in 2025Q1 from 47 million in 2024Q4 representing a change of 35.84%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 68 million in 2025Q1 from 51 million in 2024Q4 representing a change of 33.37%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 68 million in 2025Q1 from 52 million in 2024Q4 representing a change of 32.24%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 5 million in 2025Q1 from 5 million in 2024Q4 representing a change of -7.53%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of -25.7%. This indicates a reduction in overall debt burden.
Short Term Investments: Short Term Investments decreased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Retained Earnings: Retained Earnings decreased to -195 million in 2025Q1 from -190 million in 2024Q4 representing a change of -2.66%. This indicates an accumulated losses.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001808898 | |||
| net change in cash | 48439000 | -1586000 | 3,154.16 |
| operating cash flow | -19403000 | -18012000 | -7.72 |
| free cash flow | -19582000 | -18013000 | -8.71 |
| capital expenditure | -179000 | -1000 | -17,800.00 |
| depreciation and amortization | 343000 | 381000 | -9.97 |
| deferred income tax | 0 | -714000 | 100.00 |
| stock based compensation | 830000 | 452000 | 83.63 |
| accounts payables | 941000 | 1357000 | -30.66 |
| inventory | 0 | -1307000 | 100.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -179000 | -1000 | -17,800.00 |
| net cash used for investing activites | -179000 | -1000 | -17,800.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 73921000 | 17884000 | 313.34 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 68029000 | 16015000 | 324.78 |
| cash at end of period | 50929000 | 2490000 | 1,945.34 |
| accounts receivables | 0 | -50000 | 100.00 |
| cash at beginning of period | 2490000 | 4076000 | -38.91 |
Net Change in Cash: Net Change in Cash increased to 48 million in 2024 from -2 million in 2023 representing a change of 3154.16%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024 from 0 million in 2023 representing a change of -17800.0%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024 from 1 million in 2023 representing a change of -30.66%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow decreased to -19 million in 2024 from -18 million in 2023 representing a change of -7.72%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -20 million in 2024 from -18 million in 2023 representing a change of -8.71%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2024 from -1 million in 2023 representing a change of 100.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 1 million in 2024 from 0 million in 2023 representing a change of 83.63%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2024 from 0 million in 2023 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0001808898 | |||
| operating cash flow | -4586000 | -3293000 | -39.27 |
| free cash flow | -4586000 | -3293000 | -39.27 |
| capital expenditure | 0 | -565.04 | 100.00 |
| depreciation and amortization | 91000 | 91000 | 0.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 435000 | 454000 | -4.19 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 0 | 1549628 | -100.00 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -565.04 | 100.00 |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 42999000 | -100.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 21655000 | 40071000 | -45.96 |
| net change in cash | 16976000 | 36773000 | -53.84 |
| cash at end of period | 67905000 | 50929000 | 33.33 |
| cash at beginning of period | 50929000 | 14156000 | 259.77 |
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2018 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-06-30 | 2023-06-30 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 0.05 | 0.05 | -1.70 |
| net income per share | -5.36 | -14.12 | 62.05 |
| operating cash flow per share | -4.78 | -13.0 | 63.23 |
| free cash flow per share | -4.82 | -13.0 | 62.90 |
| cash per share | 12.53 | 1.79 | 600.91 |
| book value per share | 11.64 | 0.15 | 7,883.49 |
| tangible book value per share | 11.64 | 0.15 | 7,883.49 |
| shareholders equity per share | 11.64 | 0.15 | 7,883.49 |
| interest debt per share | 0.22 | 0.02 | 835.01 |
| market cap | 29476921.32 | 5626421.08 | 423.90 |
| enterprise value | -21105078.68 | 3708421.08 | -669.11 |
| pe ratio | -1.36 | -0.29 | -371.18 |
| price to sales ratio | 136.47 | 75.02 | 81.91 |
| pocfratio | -1.52 | -0.31 | -386.34 |
| pfcf ratio | -1.51 | -0.31 | -381.92 |
| pb ratio | 0.62 | 27.85 | -97.76 |
| ptb ratio | 0.62 | 27.85 | -97.76 |
| ev to sales | -97.71 | 49.45 | -297.61 |
| enterprise value over ebitda | 0.94 | -0.2 | 573.21 |
| ev to operating cash flow | 1.09 | -0.21 | 628.31 |
| ev to free cash flow | 1.08 | -0.21 | 623.51 |
| earnings yield | -0.74 | -3.48 | 78.78 |
| free cash flow yield | -0.66 | -3.2 | 79.25 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 2.25 | 0.1 | 2,092.80 |
| current ratio | 10.49 | 0.94 | 1,019.51 |
| interest coverage | -24.88 | -578.21 | 95.70 |
| income quality | 0.89 | 0.92 | -3.12 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 32.36 | 85.09 | -61.98 |
| research and ddevelopement to revenue | 72.26 | 170.32 | -57.57 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | -0.0 | -16,516.75 |
| capex to revenue | 0.83 | 0.01 | 6,115.28 |
| capex to depreciation | 0.52 | 0.0 | 19,783.09 |
| stock based compensation to revenue | 3.84 | 6.03 | -36.24 |
| graham number | 37.45 | 6.8 | 450.44 |
| roic | -0.46 | -94.47 | 99.51 |
| return on tangible assets | -0.42 | -4.38 | 90.49 |
| graham net net | 11.31 | -1.28 | 981.57 |
| working capital | 46750000 | -249000 | 18,875.10 |
| tangible asset value | 47248000 | 202000 | 23,290.10 |
| net current asset value | 46712000 | -533000 | 8,863.98 |
| invested capital | 47199000 | 364000 | 12,866.76 |
| average receivables | 0 | 1500 | -100.00 |
| average payables | 1245500 | 781000 | 59.48 |
| average inventory | 38000 | 6500.9 | 484.53 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 4565.88 | 1092.13 | 318.07 |
| days of inventory on hand | 212.92 | 12.45 | 1,609.62 |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.08 | 0.33 | -76.08 |
| inventory turnover | 1.71 | 29.31 | -94.15 |
| roe | -0.46 | -96.84 | 99.52 |
| capex per share | 0.04 | 0.0 | 6,009.61 |
ROE: Return on Equity (ROE) increased to -0.46 on 2024-06-30 from -96.84 on 2023-06-30, representing a change of 99.52%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -1.36 on 2024-06-30 from -0.29 on 2023-06-30, representing a change of -371.18%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 10.49 on 2024-06-30 from 0.94 on 2023-06-30, representing a change of 1019.51%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q1 | 2024-06-30 Q4 | Q/Q change % | |
|---|---|---|---|
| BNTC | |||
| calendar year | 2025 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.48 | -1.16 | 59.12 |
| operating cash flow per share | -0.43 | -0.81 | 46.88 |
| free cash flow per share | -0.43 | -0.81 | 46.88 |
| cash per share | 6.37 | 12.54 | -49.19 |
| book value per share | 6.03 | 11.64 | -48.19 |
| tangible book value per share | 6.03 | 11.64 | -48.19 |
| shareholders equity per share | 6.03 | 11.64 | -48.19 |
| interest debt per share | 0.08 | 0 | NaN |
| market cap | 97823258.27 | 29476921.32 | 231.86 |
| enterprise value | 30193258.27 | -21105078.68 | 243.06 |
| pe ratio | -4.83 | -1.56 | -209.63 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -21.33 | -8.95 | -138.30 |
| pfcf ratio | -21.33 | -8.95 | -138.30 |
| pb ratio | 1.52 | 0.62 | 144.31 |
| ptb ratio | 1.52 | 0.62 | 144.31 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -5.21 | 3.82 | -236.42 |
| ev to operating cash flow | -6.58 | 6.41 | -202.73 |
| ev to free cash flow | -6.58 | 6.41 | -202.73 |
| earnings yield | -0.05 | -0.16 | 67.70 |
| free cash flow yield | -0.05 | -0.11 | 58.04 |
| debt to equity | 0.0 | 0 | NaN |
| debt to assets | 0.0 | 0 | NaN |
| net debt to ebitda | 11.68 | 9.16 | 27.49 |
| current ratio | 15.01 | 10.49 | 43.02 |
| interest coverage | -9.59 | 0 | NaN |
| income quality | 0.91 | 0.7 | 29.93 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | -0.0 | 100.00 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0.01 | -100.00 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 8.03 | 17.45 | -53.98 |
| roic | -0.09 | -0.12 | 23.41 |
| return on tangible assets | -0.07 | -0.09 | 18.63 |
| graham net net | 5.94 | 11.37 | -47.75 |
| working capital | 63782000 | 46750000 | 36.43 |
| tangible asset value | 64180000 | 47248000 | 35.84 |
| net current asset value | 63741000 | 46712000 | 36.46 |
| invested capital | 64140000 | 47199000 | 35.89 |
| average receivables | 114500 | 141000 | -18.79 |
| average payables | 675500 | 1083000 | -37.63 |
| average inventory | 31500 | 31500.6 | -0.00 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 1336.15 | -100.00 |
| days of inventory on hand | 0 | 62.31 | -100.00 |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.07 | -100.00 |
| inventory turnover | 0 | 1.44 | -100.00 |
| roe | -0.08 | -0.1 | 21.09 |
| capex per share | 0 | 0.0 | -100.00 |
ROE: Return on Equity (ROE) increased to -0.08 on 2024-09-30 Q1 from -0.10 on 2024-06-30 Q4, representing a change of 21.09%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -4.83 on 2024-09-30 Q1 from -1.56 on 2024-06-30 Q4, representing a change of -209.63%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 15.01 on 2024-09-30 Q1 from 10.49 on 2024-06-30 Q4, representing a change of 43.02%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Negative Sentiment: Discounted Cash Flow value is 6.45 which is lower than current price 10.68, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 16:30:00
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society-
Sentiment: Positive
Publish Date: 2024-11-04 08:00:00
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.
Sentiment: Positive
Publish Date: 2024-10-17 15:35:10
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing.
Sentiment: Neutral
Publish Date: 2024-10-14 06:00:00
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
Sentiment: Positive
Publish Date: 2024-10-12 06:30:00
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-
Sentiment: Positive
Publish Date: 2024-09-26 16:30:00
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-
Sentiment: Positive
Publish Date: 2024-09-18 08:00:00
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czech Republic from October 8-12, 2024. The Late Breaking Abstract entitled “Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of an AAV9-based gene therapy (BB-301) Administered to Subjects with Oculopharyngeal Muscular Dystrophy (OPMD) with Dysphagia” will be presented on October 12, 2024.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
